# Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

> **NCT07221513** · PHASE2 · WITHDRAWN · sponsor: **Salubris Biotherapeutics Inc**

## Conditions studied

- HFrEF - Heart Failure With Reduced Ejection Fraction
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Group 2 Pulmonary Hypertension

## Interventions

- **DRUG:** JK07

## Key facts

- **NCT ID:** NCT07221513
- **Lead sponsor:** Salubris Biotherapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12-15
- **Primary completion:** 2026-04-16
- **Final completion:** 2026-04-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221513, "Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT07221513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*